

1 **Preliminary findings from the Dynamics of the Immune Responses to Repeat Influenza**
2 **Vaccination Exposures (DRIVE I) Study: a Randomized Controlled Trial**

3

4 Benjamin J. Cowling^{1,2}, Sook-San Wong^{1,3}, Jefferson J. S. Santos⁴, Lisa Touyon^{1,3}, Jordan
5 Ort⁴, Naiqing Ye⁴, Natalie K. M. Kwok¹, Faith Ho¹, Samuel M. S. Cheng¹, Dennis K. M. Ip¹,
6 Malik Peiris¹, Richard J. Webby⁵, Patrick C. Wilson⁶, Sophie A. Valkenburg^{3,7}, John S.
7 Tsang⁸, Nancy H. L. Leung^{1,2}, Scott E. Hensley⁴, Sarah Cobey⁹

8

9 **Affiliations:**

10 1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
11 Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong
12 Special Administrative Region, China

13 2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and Technology
14 Park, New Territories, Hong Kong Special Administrative Region, China

15 3. HKU-Pasteur Research Pole, Li Ka Shing Faculty of Medicine, The University of Hong
16 Kong, Hong Kong Special Administrative Region, China

17 4. Department of Microbiology, Perelman School of Medicine, University of Pennsylvania,
18 Philadelphia, PA 19104

19 5. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN
20 38105

21 6. Gale and Ira Drukier Institute for Children's Health, Weill Cornell Medicine, New York,
22 NY 10021

23 7. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and
24 Immunity, University of Melbourne, Melbourne, Australia

25 8. Yale Center for Systems and Engineering Immunology and Department of Immunobiology,
26 Yale University School of Medicine, New Haven, CT 06520

27 9. Department of Ecology and Evolution, University of Chicago, Chicago, IL 60637

28

29 **Corresponding author:**

30 Prof. Benjamin J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The

31 University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong

32 Tel: +852 3917 6711; Email: bcowling@hku.hk

33

34 Word count (abstract): 312

35 Word count (main text): 3,473

36 Running head: Antibody responses after repeated influenza vaccination

37 Clinicaltrials.gov: NCT04576377

38

39

40 **ABSTRACT**

41 **Background:** Studies have reported that repeated annual vaccination may influence the
42 effectiveness of the influenza vaccination in the current season. The mechanisms underlying
43 these differences are unclear but might include “focusing” of the adaptive immune response
44 to older strains.

45 **Methods:** We established a 5-year randomized placebo-controlled trial of repeated influenza
46 vaccination (Flublok, Sanofi Pasteur) in adults 18-45 years of age. Participants were
47 randomized equally between five groups, with planned annual receipt of vaccination (V) or
48 saline placebo (P) as follows: P-P-P-P-V, P-P-P-V-V, P-P-V-V-V, P-V-V-V-V, or V-V-V-V-
49 V. Serum samples were collected each year just before vaccination and after 30 and 182 days.
50 A subset of sera were tested by hemagglutination inhibition assays, focus reduction
51 neutralization tests and enzyme-linked immunosorbent assays against vaccine strains.

52 **Results:** From 23 October 2020 through 11 March 2021 we enrolled and randomized 447
53 adults. We selected sera from 95 participants at five timepoints from the first two study years
54 for testing. Among vaccinated individuals, antibody titers increased between days 0 and 30
55 against each of the vaccine strains, with substantial increases for first-time vaccinees and
56 smaller increases for repeat vaccinees, who had higher pre-vaccination titers in year 2. There
57 were statistically significant reductions in the proportion of participants achieving a four-fold
58 greater rise in antibody titer for the repeat vaccinees for A(H1N1), B/Victoria and
59 B/Yamagata, but not for influenza A(H3N2). There were no statistically significant
60 differences between groups in geometric mean titers at day 30 or the proportions of
61 participants with antibody titers ≥ 40 at day 30 for any of the vaccine strains.

62 **Conclusions:** In the first two years, repeat vaccinees and first-time vaccinees had similar
63 post-vaccination geometric mean titers to all four vaccine strains, indicative of similar levels
64 of clinical protection. The vaccine strains of A(H1N1) and A(H3N2) were updated in year 2,

65 providing an opportunity to explore antigenic distances between those strains in humans in

66 subsequent years.

67

68 Key words: influenza; vaccination; immunogenicity; antibody

69

70 INTRODUCTION

71 The efficacy of influenza vaccines has been demonstrated in randomized trials, and annual
72 influenza vaccination campaigns prevent considerable morbidity and mortality [1].
73 Continuous viral evolution necessitates regular updates to vaccine strains, and the degree of
74 match between vaccine and circulating strains affects vaccine protection [2]. A number of
75 studies have reported that repeated annual vaccination may influence the effectiveness of the
76 influenza vaccination in the current season [3-7]. The effect of repeated vaccination on
77 immunogenicity has been less frequently assessed in multi-year randomized trials, but repeat
78 vaccination effects are also observed [8-12]. The mechanisms underlying these differences
79 are unclear, but might include “focusing” of the adaptive immune response to older strains
80 [13]. Under this model, repeated exposures boost responses to conserved and potentially less
81 protective epitopes, which might in some years reduce protection against circulating strains
82 [14, 15].

83
84 Enhanced influenza vaccines, including the recombinant hemagglutinin vaccine Flublok
85 (Sanofi Pasteur), stimulate stronger immune responses and may be able to overcome repeat
86 vaccination effects. The Flublok vaccine has two major differences with the standard egg-
87 grown inactivated influenza vaccine [10, 16, 17]. First, because eggs are not used in the
88 production process for Flublok, the antigens included in the vaccine are more similar to
89 circulating viruses, circumventing the issue of egg-adapted mutations in the hemagglutinin
90 (HA) protein that can lead to antigenic mismatch [10, 18]. Second, it includes three times
91 more HA antigen than standard-dose vaccines and can therefore generate a stronger, more
92 HA-specific humoral immune response [10, 11]. Flublok has been approved by the Food and
93 Drug Administration for use in the United States in all adults ≥ 18 years of age since October
94 2014 [19]. Evidence from randomized trials have shown improved immunogenicity and

95 efficacy and a slightly lower local reactogenicity compared with standard inactivated
96 influenza vaccine in adults ≥ 18 years [20].

97

98 We designed a randomized controlled trial to explore immune responses to first-time or
99 repeated influenza vaccination with the Flublok vaccine, with a particular interest in the
100 possible occurrence of repeat vaccination effects.

101

102 **METHODS**

103 *Study design*

104 This study is a randomized controlled trial in adults 18-45 years of age at enrolment
105 (Clinicaltrials.gov: NCT04576377). Participants were enrolled from the general community
106 in Hong Kong, with study advertisements distributed via institutions (such as schools and
107 universities), organizations (such as professional associations), and local community centers,
108 and through mass promotion efforts including mass mailing to residential estates,
109 advertisements in newspapers and public transport, social media platforms (such as
110 Facebook), bulk emails, and invitation to and referrals from members of previous studies.
111 Individuals were eligible to participate if they were between 18 and 45 years of age, capable
112 of providing informed consent, and intending to reside in Hong Kong for at least the next two
113 years. Potential participants were excluded if they had been vaccinated against influenza in
114 the preceding 24 months, if they were included in a priority group for influenza vaccination
115 (e.g. healthcare worker, pregnant woman), if they had a diagnosed immunosuppressive
116 condition or were taking immunosuppressive medication, or if they had severe allergies or
117 bleeding conditions that contraindicated intramuscular influenza vaccination.

118

119 We collected a baseline 9-ml clotted blood sample from enrolled participants, and we used a
120 standardized questionnaire to collect baseline information on demographics, current health
121 status, medical history and medication use. Participants were randomized equally among five
122 equal groups using a permuted block approach with block sizes of 5 and 10, using the
123 statistical software package R. Based on the randomization scheme (Appendix Figure 1),
124 each participant would receive either influenza vaccination or placebo annually in the
125 following schedule for the first four years of the trial in the following schedule: Group 1,
126 placebo injection for all four years; Group 2, placebo for three years followed by influenza
127 vaccination in the fourth year; Group 3, placebo for two years followed by vaccination for
128 two years; Group 4, placebo in the first year and then vaccination for the subsequent three
129 years; and Group 5, vaccination in all four years. All participants would then receive
130 vaccination in the fifth and final year. Allocation to these groups was concealed using
131 REDCap [21].

132

133 The influenza vaccine used in our trial is recombinant HA quadrivalent influenza vaccine
134 (0.5mL Flublok®, Sanofi Pasteur) for the northern hemisphere. For the 2020/21 northern
135 hemisphere influenza season, it was formulated to contain 180 mg HA per 0.5-mL dose, with
136 45 mg HA of each of the following four influenza virus strains: A/Hawaii/70/2019 (H1N1),
137 A/Minnesota/41/2019 (an A/Hong Kong/45/2019-like virus) (H3N2), B/Washington/02/2019
138 and B/Phuket/3073/2013. In 2021/22 the influenza B strains were unchanged while the
139 influenza A strains were updated to A/Wisconsin/588/2019 (H1N1) and
140 A/Tasmania/503/2020 (an A/Cambodia/e0826360/2020-like virus) (H3N2) (Appendix Table
141 1). To maintain blinding of participants, we used 0.5 ml saline placebo in syringes prepared
142 in advance and packed the vaccines and placebo doses in numbered boxes according to the

143 randomization scheme. Other than the nurse who conducted the injections, all other study
144 staff were blinded to the study intervention.

145

146 Following vaccination, we invited participants to return for scheduled follow-up visits at 30
147 days and 182 days after vaccination for further blood draws. In a subset of participants we
148 arranged for collection of peripheral blood mononuclear cells at baseline, day 7 and day 30,
149 and additional clotted blood samples on days 91 and 273. All participants were invited to
150 report any acute respiratory illnesses. During periods of influenza activity, we planned to
151 implement weekly active illness surveillance, collecting nasal swabs from ill participants for
152 testing by PCR and an additional blood sample 30 days after illness onset.

153

154 ***Ethics***

155 Written informed consent was obtained from all participants. Participants were compensated
156 with a gift voucher worth HK\$100 (US\$13) at each blood draw. The study protocol was
157 approved by the Institutional Review Boards of the University of Hong Kong (ref: UW19-
158 551) and of the University of Chicago Biological Sciences Division (ref: IRB20-0217).

159

160 ***Primary and secondary outcomes***

161 The primary outcome measure in this trial is the vaccine immunogenicity, measured in terms
162 of antibody titers in hemagglutination-inhibition (HAI) assays or foci reduction neutralization
163 tests (FRNTs) for each vaccine strain. We compared the proportion of participants who
164 achieved the targeted rise in antibody titre against each of the vaccine strains at 30 days. The
165 targeted rise in antibody titre is defined as a four-fold or greater rise in titer, including either a
166 pre-vaccination HAI titer <10 and a post-vaccination HAI titre ≥ 20 or a pre-vaccination HAI
167 titer ≥ 10 and at least a four-fold rise in post-vaccination HAI antibody titer. We also assessed

168 the geometric mean titer (GMT) ratios between the various randomized groups against each
169 of the vaccine strains at 30 days and 182 days. HAI assays were completed with A(H1N1)
170 and influenza B viruses; however, we used FRNTs to quantify antibodies against A(H3N2)
171 strains, since some contemporary A(H3N2) strains inefficiently agglutinate red blood cells
172 [10, 22]. Since the FRNT dilution series started at 20 instead of 10 due to the assay design,
173 we defined a targeted rise for antibody titers against A(H3N2) measured by FRNT as a 4-fold
174 rise to a post-vaccination titer of ≥ 40 .

175

176 Other secondary outcomes specified in the protocol include additional comparisons of
177 antibody titers; analyses of cellular immunity, including transcriptional activity of immune
178 cells; comparisons of adverse reactions after vaccination; and the occurrence of influenza or
179 other acute respiratory illnesses. These secondary outcomes will be addressed in subsequent
180 reports. Of particular note, there was no influenza circulation in Hong Kong between March
181 2020 and February 2023, which included the first two years of the trial [23]. Only a few
182 influenza virus infections were detected by the local public health laboratory during this
183 period, and they were mostly in arriving travelers and children shedding live attenuated
184 vaccine virus [24, 25].

185

186 ***Laboratory analysis***

187 Blood samples were collected in tubes for clotted blood, stored in a refrigerated container at
188 2-8°C immediately and delivered to the laboratory within two days for further processing.
189 Serum specimens were aliquoted and stored at -80°C prior to subsequent testing. Serum
190 samples were treated with receptor destroying enzyme (RDE) and tested by HAI against the
191 influenza A(H1N1) and B vaccine strains using a standard protocol [26]. For influenza
192 A(H1N1), the vaccine strains were A/Hawaii/70/2019 in 2020/21 (GISAID Accession #

193 EPI397028) and A/Wisconsin/588/2019 (GISAID Accession # EPI404460) in 2021/22. Due
194 to the inability to obtain sufficient volume of cell-grown virus stock, A/Wisconsin/588/2019
195 was eventually propagated once in eggs. A single mutation D204V was found in the egg-
196 grown stock. A comparison of antigenicity using 22 serum samples from five participants
197 showed that assay with the egg-grown stock had slightly higher sensitivity that yielded 2-fold
198 higher titers in 50% of the samples but otherwise showed good correlation with cell-grown
199 stock (Appendix Figure 2). For influenza B, ether-treated egg-grown antigens were used, and
200 the vaccine strains were B/Washington/02/2019 (GISAID Accession # EPI347829) and
201 B/Phuket/3073/2014 (GISAID Accession # EPI168822) in both years. We used a focus
202 reduction neutralization test (FRNT) for the two influenza A(H3N2) vaccine strains A/Hong
203 Kong/45/2019 in 2020/21 and A/Cambodia/e0826360/2020 in 2021/22. A/Hong
204 Kong/45/2019 HA (GISAID Accession # EPI1397376) is identical at the amino acid level to
205 A/Minnesota/41/2019 HA (GISAID Accession # EPI1487157) included in the Flublok for
206 2020/21 influenza season. However, A/Cambodia/e0826360/2020 HA (GISAID Accession #
207 EPI1837753) differs by a single amino acid substitution (N171K at antigenic site D) from
208 A/Tasmania/503/2020 HA (GISAID Accession # EPI1759269) included in the Flublok for
209 2021/22 influenza season. Both influenza A(H3N2) virus strains were generated by reverse
210 genetics using A/Puerto Rico/8/1934 internal genes [27]. FRNT assays were completed as
211 previously described [28].

212

213 To estimate total binding antibody of specific IgG responses, Enzyme Linked Immunosorbent
214 Assays (ELISAs) were performed with recombinant HA (rHA) of the A(H1N1) vaccine
215 strains A/Hawaii/70/2019 in 2020/21 and A/Wisconsin/588/2019, and the A(H3N2) vaccine
216 strains A/Minnesota/41/2019 and A/Tasmania/503/2020 (Appendix Table 1). The HA stalk

217 monoclonal antibody CR9114 was used as an internal control on each plate. Expression and
218 purification of rHAs and CR9114 was performed as previously described [29].

219

220 *Sample size justification*

221 We aimed to enroll 820 participants into our study. This would permit us to have a sample
222 size of at least 100 participants in each of the five groups at the fourth year of follow-up,
223 allowing for an anticipated drop-out rate of 15% per year without replacement. Most of our
224 outcome measures, including both of our primary outcome measures, are based on geometric
225 mean antibody titers. In year 2, with a target sample size of 139 in each group, we expected
226 to have 80% power to identify 1.6-fold differences in GMT between groups, assuming a
227 standard deviation of $\log_2(\text{GMT})$ of 1.8. However, due to disruption in study activities during
228 the COVID-19 pandemic we were unable to reach our target sample size, and as a
229 consequence we updated the protocol to include enrolment of an additional cohort of 530
230 participants starting in 2021/22 with a similar trial design, with participants randomized
231 across four groups instead of five, and receiving four annual doses of vaccination/placebo as
232 part of the study instead of five. Results from the second cohort with participant enrolment in
233 2021/22, named DRIVE II, will be reported in due course. For consistency, the present cohort
234 with participant enrolment in 2020/21 is named DRIVE I.

235

236 *Statistical analysis*

237 We assessed the proportion of participants who achieved a 4-fold or greater rise in antibody
238 titre against each of the vaccine strains at 30 days, and compared these proportions between
239 the vaccine-vaccine, placebo-vaccine and placebo-placebo groups using Fisher exact tests,
240 pooling the three placebo-placebo groups together. We estimated GMT ratios versus the
241 placebo group at day 30 of year 2 and compared them between first-time vaccines and repeat

242 vaccinees using t-tests on the log-transformed GMT ratios. Confidence intervals were
243 estimated using t distributions. All analyses were conducted in R version 4.2.1 (R Foundation
244 for Statistical Computing, Vienna, Austria). Data and R syntax will be made available after
245 publication.

246

247 **RESULTS**

248 From 23 October 2020 through 11 March 2021, 447 individuals were enrolled and received
249 influenza vaccination or placebo according to the randomization scheme, with 88 to 91
250 individuals in each arm (Figure 1). The median age of participants was 31 years, and 54%
251 were male, with similar characteristics across the five arms (Table 1). None of the
252 participants reported receiving influenza vaccination in the two years prior to the start of the
253 trial, and only 12% reported ever previously receiving influenza vaccination. We randomly
254 selected for laboratory analysis a subset of 15 participants from groups 1-3 (who received
255 placebo in both years), 40 participants from group 4 (placebo followed by vaccination), and
256 40 participants from group 5 (vaccination in both years), and noted similar characteristics in
257 this subset to the overall participants (Appendix Table 2).

258

259 Antibody titers increased between days 0 and 30 against each of the vaccine strains, with
260 greater fold increases for first-time vaccinees compared to repeat vaccinees, while the repeat
261 vaccinees had higher antibody titers prior to vaccination in year 2 (Figure 2). At day 30 of
262 year 2, the GMTs were similar in the first-time vaccinees and repeat vaccinees (groups 4 and
263 5, respectively) for each strain analyzed (Appendix Table 4). While there were statistically
264 significant reductions in the proportion achieving a four-fold greater rise in antibody titer for
265 the repeat vaccinees in year 2 for A(H1N1), B/Victoria and B/Yamagata, there were no

266 statistically significant differences in GMTs at day 30 or the proportions with antibody titers
267 ≥ 40 at day 30 for any of the strains (Table 2).

268

269 The A(H1N1) and A(H3N2) components of the northern hemisphere vaccine were updated
270 between 2020/21 and 2021/22. For each subtype, we examined whether vaccination with
271 one strain increased antibody titers to the other, which is a measure of cross-reactivity or
272 antigenic distance. We focused on the responses in first-time vaccinees in each of the two
273 years (i.e. group 5 in year 1 and group 4 in year 2). For A(H1N1), the year 1 GMT at day 30
274 was approximately 3.2-fold higher to the 2020/21 vaccine strain (A/Hawaii/70/2019) than to
275 the vaccine strain used the next year (A/Wisconsin/588/2019), consistent with a modest
276 antigenic distance between the two strains (Table 3). For A(H3N2), the fold-difference
277 between the day 30 GMT to the 2020/21 strain (A/Hong Kong/45/2019) and the 2021/22
278 strain (A/Cambodia/e0826360/2020) was approximately 3.1, also indicating modest
279 antigenic distance.

280

281 The results in year 2 showed contrasting patterns, in that first-time vaccinees mounted
282 slightly stronger responses to the prior-season vaccine strains than to the current-season
283 vaccine strains. First-time vaccinees in year 2 had slightly higher day 30 GMTs to A(H1N1)
284 A/Wisconsin/588/2019 (the vaccine strain) than did first-time vaccinees receiving
285 A/Hawaii/70/2019 the previous year (60.6 vs. 40), but first-time vaccinees in year 2 had
286 approximately threefold higher titers to the previous year's strain, A/Hawaii/70/2019, than
287 to the strain with which they were vaccinated (180.6 vs. 60.6, respectively) (Table 3).
288 Similarly, first-time vaccinees in year 2 mounted approximately 1.5-fold higher titers to the
289 previous year's H3N2 strain than they did to the H3N2 strain in the vaccine (67.2 to A/Hong
290 Kong/45/2019 and 45.6 to A/Cambodia/e0826360/2020). Similar to the patterns for H1N1,

291 first-time vaccinees had slightly higher absolute post-vaccination titers to the vaccine strain
292 (A/Cambodia/e0826360/2020) compared to individuals vaccinated with A/Hong
293 Kong/45/2019 the previous year (titers of 45.6 vs. 34.7), showing the strain update still led
294 to increased titers to the intended strain.

295

296 That first-time vaccinees in year 2 mounted higher titers to the prior year's influenza A
297 vaccine strains than to the current vaccine strains might reflect a strong influence of prior
298 immunity, but it could also reflect differences in receptor avidity between the strains. Viruses
299 that bind to cells with lower avidity are more easily neutralized by antibodies compared to
300 viruses that bind with higher avidity, irrespective of antigenic differences [30]. To address
301 this, we measured total HA-specific IgG antibody responses by ELISAs which are not
302 affected by differences in viral receptor binding avidities, to measure antibody binding to the
303 influenza A(H1N1) and A(H3N2) vaccine strains, with results shown in Figure 3 and Table 3.
304 We found that the year 2, geometric mean day 30 antibody levels to the current vaccine strain
305 were similar to or slightly higher than those to the previous vaccine strain in first-time
306 vaccinees, suggesting no disproportionate boosting of prior immunity targeting past strains.
307 That there were no statistically significant differences in the geometric mean post-vaccination
308 antibody levels measured by ELISA between first-time vaccinees in years 1 and 2 suggests
309 the previously reported low HAI and FRNT titers to A/Wisconsin/588/2019 and
310 A/Cambodia/e0826360/2020 thus likely arise from differences in the receptor avidity. The
311 antigenic distances implied by the ELISA data are also smaller and do not show the same
312 asymmetry as before. For instance, the amount of antibody reactive to A/Wisconsin/588/2019
313 after vaccination with A/Hawaii/70/2019 (group 5, year 1, day 30) was similar to the amount
314 of antibody reactive to A/Hawaii/70/2019 after vaccination with A/Wisconsin/588/2019
315 (group 4, year 2, day 30) (Table 3). Finally, consistent with the data from the HAI and FRNT

316 assays, there were no statistically significant differences in absolute post-vaccination
317 antibody levels measured by ELISA between first-time and repeat vaccinees in year 2.

318

319 **DISCUSSION**

320 In the second year of this five-year trial we identified reduced fold-rises in HAI titers after
321 repeat vaccination for influenza A(H1N1), B/Victoria and B/Yamagata (Figure 2). However,
322 post-vaccination GMTs were similar in repeat vaccinees and first-time vaccinees, indicating
323 that these reduced responses likely would not hinder overall protection assuming that the
324 post-vaccination HAI titer correlates with protection for Flublok [31]. During the study
325 period, public health measures used to contain COVID-19 also prevented the community
326 circulation of influenza [23], and our analysis of antibody titers is therefore unaffected by any
327 potential differences in incidence of influenza virus infections in vaccine versus placebo
328 recipients in the first year of the study that could have occurred if influenza had been
329 circulating.

330

331 In year 2 of our study we found that repeat and first-time vaccinees also had similar post-
332 vaccination GMTs to A(H3N2) measured by FRNT (Figure 2), indicative of similar levels of
333 clinical protection. However, there was no substantial blunting of the fold rises to A(H3N2)
334 in repeat vaccinees. Both groups started with low GMTs to A/Cambodia/e0826360/2020
335 (H3N2) in year 2 and increased those GMTs approximately 4-fold by 30 days post-
336 vaccination (Figure 2, Appendix Table 4). Our ELISA analyses measuring direct antibody
337 binding suggest that the observed differences in HAI and FRNT titers between groups could
338 be due to differences in receptor binding avidities of the viral strains used in our studies.

339

340 Both the A(H1N1) and A(H3N2) vaccine strains were updated between years 1 and 2 of the
341 study, raising opportunities to investigate the cross-reactivity of antibody titers induced by
342 vaccination. The 2020/21 vaccine induced HAI titers to A(H1N1) and FRNT titers to
343 A(H3N2) that were approximately 3-fold lower to the strains used in the 2021/22 vaccine.
344 The suggested benefits of a vaccine update were evidenced by slightly higher titers to those
345 strains among first-time vaccinees the following season compared to titers of vaccinees from
346 the 2020/21 season. However, first-time vaccinees in the 2021/22 season did not have titers
347 that were three-fold lower to strains from the 2020/21 season, as might be expected after
348 vaccination in naïve animals or associated cartographic methods. Instead, individuals
349 vaccinated in 2021/22 had approximately 3-fold and approximately 1.5-fold higher post-
350 vaccination GMTs to prior season's A(H1N1) and A(H3N2) vaccine strains. Measuring anti-
351 HA antibody responses with ELISA implied even higher cross-reactivity and limited
352 antigenic distances between viral strains used in successive years. These results suggest a
353 need to interrogate antibody responses through multiple measures and to understand how
354 each relates to protection from infection, disease and transmission.

355

356 Our study has a number of limitations. To preserve specimens for later longitudinal analyses,
357 we have analyzed a subset of participants from the original study, and thus are limited in the
358 effect sizes we can detect in the present analysis. Future analyses might yield different results.
359 While the strains used in our serologic assays did not have 100% sequence identity with the
360 vaccine strains, the minor genetic differences likely did not affect our major conclusions.
361 Additionally, although the ELISA data suggest that antibody responses were comparable in
362 magnitude between year 1 and 2 influenza A vaccine strains, at present we cannot conclude
363 whether the contrasting HAI and FRNT results reflect strain-specific differences in receptor
364 binding avidity, neutralization potential, and/or the relative immunogenicity of the stalk and

365 other epitopes that are poorly measured by HAI. Understanding the roles of these factors is an
366 important area for further work [32].

367

368 In conclusion, our randomized clinical trial of repeat influenza vaccination has found that
369 repeat vaccination can be associated with reduced fold changes in antibody titers, but our
370 preliminary results show no evidence of reduced post-vaccination mean titers, consistent with
371 similar levels of protection after vaccination regardless of vaccination history. The apparently
372 low immunogenicity of influenza A vaccine strains in 2021/22 relative to the prior year may
373 reflect increases in receptor avidity of updated vaccine strains and deserves further study.

374

375

376 **ACKNOWLEDGMENTS**

377 The authors thank Suk Yee Chan, Tin Kin Chau, Trushar Jeevan, Pat Kaewpreedee, Ida Lam,
378 Erica Lau, Kelly Lee, Maggie Lo, Charlie Man, Tiffany Ng, Yammy Ng, Yvonne Ng, Eunice
379 Shiu, Lewis Siu, Tiffany Tavares, Ivan Tsai, Lilly Wang, Angel Wong, Irene Wong, Miyuki
380 Wong, Phebe Yeung, and Zoe Xiao for technical support, and Julie Au and Ada Lee for
381 administrative support.

382

383 **FUNDING**

384 This project was supported by federal funds from the National Institute of Allergy and
385 Infectious Diseases, National Institutes of Health, Department of Health and Human Services
386 (grant no. U01 AI153700 and contract nos. 75N93021C00015 and 75N93021C00016), and
387 the Theme-based Research Scheme (Project No. T11-712/19-N) of the Research Grants
388 Council of the Hong Kong SAR Government. BJC is supported by an RGC Senior Research
389 Fellowship (grant number: HKU SRFS2021-7S03).

390

391 **POTENTIAL CONFLICTS OF INTEREST**

392 B.J.C. consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna,
393 Novavax, Pfizer, Roche and Sanofi Pasteur. S.C. has consulted for Seqirus. S.E.H. is a co-
394 inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform.
395 S.E.H reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck.
396 The authors report no other potential conflicts of interest.

397

398 **REFERENCES**

- 399 1. Chung JR, Rolfes MA, Flannery B, et al. Effects of Influenza Vaccination in the United
400 States During the 2018-2019 Influenza Season. *Clin Infect Dis* **2020**; 71:e368-e76.
- 401 2. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by
402 subtype: a systematic review and meta-analysis of test-negative design studies. *Lancet Infect*
403 *Dis* **2016**; 16:942-51.
- 404 3. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of Repeated Vaccination on
405 Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons. *Clin Infect Dis*
406 **2014**; 59:1375-85.
- 407 4. Skowronski DM, Chambers C, Sabaiduc S, et al. A Perfect Storm: Impact of Genomic
408 Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-
409 2015 Season. *Clin Infect Dis* **2016**; 63:21-32.
- 410 5. Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G.
411 Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. *Expert*
412 *Rev Vaccines* **2017**; 16:1-14.
- 413 6. Ramsay LC, Buchan SA, Stirling RG, et al. The impact of repeated vaccination on
414 influenza vaccine effectiveness: a systematic review and meta-analysis. *BMC Med* **2019**;
415 17:9.
- 416 7. Jones-Gray E, Robinson EJ, Kucharski AJ, Fox A, Sullivan SG. Does repeated influenza
417 vaccination attenuate effectiveness? A systematic review and meta-analysis. *Lancet Respir*
418 *Med* **2023**; 11:27-44.
- 419 8. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP.
420 Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-
421 Dose Inactivated Influenza Vaccine in Older Adults. *Clin Infect Dis* **2016**; 62:1092-9.

- 422 9. Thompson MG, Naleway A, Fry AM, et al. Effects of repeated annual inactivated
423 influenza vaccination among healthcare personnel on serum hemagglutinin inhibition
424 antibody response to A/Perth/16/2009 (H3N2)-like virus during 2010-11. *Vaccine* **2016**;
425 34:981-8.
- 426 10. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a
427 glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains.
428 *Proc Natl Acad Sci U S A* **2017**; 114:12578-83.
- 429 11. Gouma S, Zost SJ, Parkhouse K, et al. Comparison of Human H3N2 Antibody Responses
430 Elicited by Egg-Based, Cell-Based, and Recombinant Protein-Based Influenza Vaccines
431 During the 2017-2018 Season. *Clin Infect Dis* **2020**; 71:1447-53.
- 432 12. Leung VKY, Fox A, Carolan LA, et al. Impact of prior vaccination on antibody response
433 and influenza-like illness among Australian healthcare workers after influenza vaccination in
434 2016. *Vaccine* **2021**; 39:3270-8.
- 435 13. Smith DJ, Forrest S, Ackley DH, Perelson AS. Variable efficacy of repeated annual
436 influenza vaccination. *PNAS* **1999**; 96:14001-6.
- 437 14. Skowronski DM, Chambers C, De Serres G, et al. Serial Vaccination and the Antigenic
438 Distance Hypothesis: Effects on Influenza Vaccine Effectiveness During A(H3N2)
439 Epidemics in Canada, 2010-2011 to 2014-2015. *J Infect Dis* **2017**; 215:1059-99.
- 440 15. Monto AS, Malosh RE, Petrie JG, Martin ET. The Doctrine of Original Antigenic Sin:
441 Separating Good From Evil. *J Infect Dis* **2017**; 215:1782-8.
- 442 16. Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. *Vaccines*
443 (Basel) **2018**; 6.
- 444 17. Cox MM, Patriarca PA, Treanor J. FluBlok, a recombinant hemagglutinin influenza
445 vaccine. *Influenza Other Respir Viruses* **2008**; 2:211-9.

- 446 18. Yang LP. Recombinant trivalent influenza vaccine (flublok((R))): a review of its use in
447 the prevention of seasonal influenza in adults. *Drugs* **2013**; 73:1357-66.
- 448 19. Izikson R, Leffell DJ, Bock SA, et al. Randomized comparison of the safety of
449 Flublok((R)) versus licensed inactivated influenza vaccine in healthy, medically stable adults
450 \geq 50 years of age. *Vaccine* **2015**; 33:6622-8.
- 451 20. Cox MM, Izikson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok
452 in the prevention of seasonal influenza in adults. *Ther Adv Vaccines* **2015**; 3:97-108.
- 453 21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
454 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
455 translational research informatics support. *J Biomed Inform* **2009**; 42:377-81.
- 456 22. Allen JD, Ross TM. H3N2 influenza viruses in humans: Viral mechanisms, evolution,
457 and evaluation. *Hum Vaccin Immunother* **2018**; 14:1840-7.
- 458 23. Xiong W, Cowling BJ, Tsang TK. Influenza Resurgence after Relaxation of Public
459 Health and Social Measures, Hong Kong, 2023. *Emerg Infect Dis* **2023**; 29:2556-9.
- 460 24. Mak GCK, Lau SSY, Lam ETK, Ng KHL, Chan RCW. Domination of influenza vaccine
461 virus strains in Hong Kong, 2021. *Influenza Other Respir Viruses* **2022**; 16:1191-3.
- 462 25. Mak GCK, Lau SSY, Wong KKY, Lau AWL, Hung DLL. Low prevalence of seasonal
463 influenza viruses in Hong Kong, 2022. *Influenza Other Respir Viruses* **2023**; 17:e13123.
- 464 26. WHO Global Influenza Surveillance Network. WHO global influenza surveillance
465 network: Manual for the laboratory diagnosis and virological surveillance of influenza.
466 Available at:
467 https://iris.who.int/bitstream/handle/10665/44518/9789241548090_eng.pdf?sequence=1.
- 468 27. Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of
469 Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015
470 Influenza Season. *Cell Rep* **2015**; 12:1-6.

- 471 28. Gouma S, Weirick M, Hensley SE. Antigenic assessment of the H3N2 component of the
472 2019-2020 Northern Hemisphere influenza vaccine. *Nat Commun* **2020**; 11:2445.
- 473 29. Bolton MJ, Santos JJS, Arevalo CP, et al. IgG3 subclass antibodies recognize
474 antigenically drifted influenza viruses and SARS-CoV-2 variants through efficient bivalent
475 binding. *Proc Natl Acad Sci U S A* **2023**; 120:e2216521120.
- 476 30. Fazekas S, Groth S. Antigenic, Adaptive and Adsorptive Variants of the Influenza a
477 Hemagglutinin. In: Laver, W.G., Bachmayer, H., Weil, R. (eds) *The Influenza Virus*
478 *Hemagglutinin*. Topics in Infectious Diseases, vol 3. Springer, Vienna.
479 https://doi.org/10.1007/978-3-7091-4130-4_3. In: Laver WG, Bachmayer H, Weil R, eds.
480 *The Influenza Virus Hemagglutinin Topics in Infectious Diseases*, vol 3. Vienna: Springer,
481 **1978**.
- 482 31. Treanor JJ, El Sahly H, King J, et al. Protective efficacy of a trivalent recombinant
483 hemagglutinin protein vaccine (FluBlok(R)) against influenza in healthy adults: a randomized,
484 placebo-controlled trial. *Vaccine* **2011**; 29:7733-9.
- 485 32. Loes AN, Tarabi RAL, Huddleston J, et al. High-throughput sequencing-based
486 neutralization assay reveals how repeated vaccinations impact titers to recent human H1N1
487 influenza strains. *bioRxiv* **2024**:2024.03.08.584176.
- 488
- 489

490 **FIGURE LEGENDS**

491 Figure 1. Study flow chart showing participant enrolment into the study, randomization into
492 five groups, interventions received, and follow up.

493 Footnote: *The random samples were selected from participants who provided serum
494 samples at these five timepoints: year 1 day 0, day 30 and day 182, and year 2 day 0 and day
495 30.

496

497 Figure 2. Antibody titers at various timepoints measured by hemagglutination inhibition
498 assay for influenza A(H1N1) and B, and by focus reduction neutralization test for influenza
499 A(H3N2). Measured titers are plotted for each group at 0, 30 and 182 days post-vaccination
500 of year 1 and at 0 and 30 days post-vaccination of year 2, and lines represent the geometric
501 mean titers at each timepoint. Data from group 5, receiving vaccine in both years, are shown
502 in red. Data from group 4, receiving placebo in year 1 and vaccine in year 2, are shown in
503 blue. Data from the other groups, receiving placebo in both years, are shown in gray.

504

505 Figure 3. Antibody levels at various timepoints measured by enzyme-linked immunosorbent
506 assay for influenza A(H1N1) and A(H3N2). Measured titers are plotted at 0 and 30 days post-
507 vaccination in years 1 and 2, and lines represent the geometric mean antibody levels at each
508 timepoint. Data from group 5, receiving vaccine in both years, are shown in red. Data from
509 group 4, receiving placebo in year 1 and vaccine in year 2, are shown in blue. Data from the
510 other groups, receiving placebo in both years, are shown in gray.

511

512

513 Table 1. Characteristics of participants randomized to different vaccination strategies

Characteristic	Randomized allocation to receipt of placebo (P) or influenza vaccination (V) in five consecutive years				
	Group 1 P-P-P-P-V (n=90)	Group 2 P-P-P-V-V (n=91)	Group 3 P-P-V-V-V (n=88)	Group 4 P-V-V-V-V (n=90)	Group 5 V-V-V-V-V (n=88)
Age at randomization					
18-25 years	27 (30%)	27 (30%)	34 (39%)	22 (24%)	20 (23%)
26-35 years	32 (36%)	32 (35%)	28 (32%)	34 (38%)	34 (39%)
36-45 years	31 (34%)	32 (35%)	26 (30%)	34 (38%)	34 (39%)
Male sex	48 (53%)	60 (66%)	42 (48%)	46 (51%)	44 (50%)
Reported receipt of influenza vaccination in the two years prior to the trial	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Reported ever receiving influenza vaccination prior to the trial	11 (12%)	11 (12%)	15 (17%)	9 (10%)	9 (10%)

514

515

516 Table 2. Antibody responses to influenza vaccination and placebo in year 2 of the trial, with 95%
 517 confidence intervals. Antibody responses were measured by HAI for influenza A(H1N1) and B, and
 518 by FRNT for influenza A(H3N2).

Outcome and Virus	Groups 1-3 (P-P) (n=15)	Group 4 (P-V) (n=40)	Group 5 (V-V) (n=40)	p-value comparing group 5 (V-V) and group 4 (P-V)
<i>Proportion with ≥4-fold rise in antibody titer from day 0 to day 30 post-vaccination*</i>				
A/Wisconsin/588/2019 (H1N1)	13% (1.6%, 40%)	78% (62%, 89%)	45% (29%, 62%)	0.005
A/Cambodia/e0826360/2020 (H3N2)	0% (0%, 21%)	60% (43%, 75%)	53% (36%, 68%)	0.65
B/Washington/02/2019	6.7% (0.2%, 32%)	70% (53%, 83%)	25% (13%, 41%)	<0.001
B/Phuket/3073/2013	0% (0%, 22%)	68% (51%, 81%)	10% (0.3%, 24%)	<0.001
<i>Antibody GMT ratio at day 30 post-vaccination compared to P-P reference group</i>				
A/Wisconsin/588/2019 (H1N1)	-	7.64 (4.0, 15)	5.59 (3.1, 10)	-
A/Cambodia/e0826360/2020 (H3N2)	-	3.97 (2.4, 6.4)	5.65 (3.6, 8.8)	-
B/Washington/02/2019	-	4.14 (1.9, 9.2)	2.83 (1.3, 6.0)	-
B/Phuket/3073/2013	-	4.65 (2.4, 9.1)	3.91 (2.0, 7.8)	-
<i>Antibody GMT ratio at day 30 post-vaccination compared to P-V reference group</i>				
A/Wisconsin/588/2019 (H1N1)	-	-	0.73 (0.37, 1.43)	0.36
A/Cambodia/e0826360/2020 (H3N2)	-	-	1.42 (0.79, 2.55)	0.23
B/Washington/02/2019	-	-	0.68 (0.36, 1.29)	0.23
B/Phuket/3073/2013	-	-	0.84	0.42

(0.55, 1.29)

Proportion with antibody titer ≥ 40 at day 30 post-vaccination

A/Wisconsin/588/2019 (H1N1)	20% (4.3%, 48%)	78% (62%, 89%)	78% (62%, 89%)	1.00
A/Cambodia/e0826360/2020 (H3N2)	13% (1.7%, 40%)	75% (59%, 87%)	85% (70%, 94%)	0.40
B/Washington/02/2019	53% (26%, 79%)	88% (73%, 96%)	88% (73%, 96%)	1.00
B/Phuket/3073/2013	87% (60%, 98%)	100% (91%, 100%)	98% (87%, 100%)	1.00

519 *For influenza A(H1N1) and B this was defined as either a pre-vaccination antibody titer < 10 and a
 520 post-vaccination antibody titre ≥ 20 , or a pre-vaccination antibody titer ≥ 10 and at least a four-fold rise
 521 in post-vaccination antibody titer. For influenza A(H3N2) this was defined as either a pre-vaccination
 522 antibody titer < 20 and a post-vaccination antibody titre ≥ 40 , or a pre-vaccination antibody titer ≥ 20
 523 and at least a four-fold rise in post-vaccination antibody titer.

524 Table 3. Geometric mean antibody levels 30 days post-vaccination for participants receiving
 525 vaccination for the first time in the study

Study arm and year	A(H1N1)		A(H3N2)		B/Vic	B/Yam
	A/Hawaii/70/2019	A/Wisconsin/588/2019	A/Minnesota/41/2019	A/Tasmania/503/2020	B/Washington/02/2019	B/Phuket/3073/2013
Assay	HAI	HAI [‡]	FRNT*	FRNT [†]	HAI	HAI
Group 5 in Year 1	127.7	40.0	107.4	34.7	61.7	273.8
Group 4 in Year 2	180.6	60.6	67.2	45.6	72.1	234.3
Assay	ELISA	ELISA	ELISA	ELISA		
Group 5 in Year 1	14400	5920	51100	34600	-	-
Group 4 in Year 2	19200	18000	48600	68500	-	-

526 Cells in bold indicate homologous responses to vaccine strains. Values for all three assays are
 527 antibody titers.

528 [‡] This virus contained an egg adaptation, D187V.

529 * The similar virus A/Hong Kong/45/2019 was used in place of A/Minnesota/41/2019 for the FRNT
 530 assay

531 [†] The similar virus A/Cambodia/e0826360/2020 was used in place of A/Tasmania/503/2020 for the
 532 FRNT assay

533

Enrollment

Assessed for eligibility (n=844)

Excluded (n=314)
• Not meeting inclusion criteria (n=257)
• Declined to participate (n=87)
• Other reasons (n=0)

Randomization

Randomized (n=447)

Allocated to Group 1 (n=90)
Year 1 – Placebo
• Received allocated intervention (n=90)
• Did not receive allocated intervention (n=0)

Allocated to Group 2 (n=91)
Year 1 – Placebo
• Received allocated intervention (n=91)
• Did not receive allocated intervention (n=0)

Allocated to Group 3 (n=88)
Year 1 – Placebo
• Received allocated intervention (n=88)
• Did not receive allocated intervention (n=0)

Allocated to Group 4 (n=90)
Year 1 – Placebo
• Received allocated intervention (n=90)
• Did not receive allocated intervention (n=0)

Allocated to Group 5 (n=88)
Year 1 – Vaccine
• Received allocated intervention (n=88)
• Did not receive allocated intervention (n=0)

Follow-up

Lost to follow-up (n=20)*
Year 2 – Placebo
• Received allocated intervention (n=70)
• Did not receive allocated intervention (n=0)

Lost to follow-up (n=22)*
Year 2 – Placebo
• Received allocated intervention (n=69)
• Did not receive allocated intervention (n=0)

Lost to follow-up (n=13)*
Year 2 – Placebo
• Received allocated intervention (n=75)
• Did not receive allocated intervention (n=0)

Lost to follow-up (n=17)*
Year 2 – Vaccine
• Received allocated intervention (n=73)
• Did not receive allocated intervention (n=0)

Lost to follow-up (n=14)*
Year 2 – Vaccine
• Received allocated intervention (n=74)
• Did not receive allocated intervention (n=0)

Analysis

PLACEBO-PLACEBO
Analyzed (n=15)
Random sample from the 171 participants from groups 1-3 who received intervention in year 2 and provided serum samples at all five timepoints*

The remainder were excluded from analysis (n=199)


PLACEBO-VACCINE
Analyzed (n=40)
Random sample from the 59 participants from group 4 who received intervention in year 2 and provided serum samples at all five timepoints*

The remainder were excluded from analysis (n=33)


VACCINE-VACCINE
Analyzed (n=40)
Random sample from the 61 participants from group 5 who received intervention in year 2 and provided serum samples at all five timepoints*

The remainder were excluded from analysis (n=34)


A/Hawaii/70/2019 (H1N1)pdm09




A/Wisconsin/588/2019 (H1N1)pdm09




A/Hong Kong/45/2019 (H3N2)




A/Cambodia/e0826360/2020 (H3N2)




B/Washington/02/2019 (B/Victoria lineage)




B/Phuket/3073/2013 (B/Yamagata lineage)




A/Hawaii/70/2019 (H1N1)pdm09



A/Wisconsin/588/2019 (H1N1)pdm09



A/Minnesota/41/2019 (H3N2)



A/Tasmania/503/2020 (H3N2)

